Concepedia

Mikel Lipschitz

ML

18

Publications

2.3K

Citations

15

H-Index

2016

Active since

Affiliations

Brigham and Women's Hospital(Current)

Dana-Farber Cancer Institute

Massachusetts General Hospital

Harvard University

University of Washington

Mikel Lipschitz is an author at Brigham and Women's Hospital specializing in medicine, radiation oncology, and cell biology.

ORCID

Top concepts

Publications per year

2016–2021

18

Publications

18

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

Suzanne George, Diana Miao, George D. Demetri et al. · Immunity · 2017 · 470 citations · Full text

, , +8

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Caron A. Jacobson, Bradley D. Hunter, Robert Redd et al. · Journal of Clinical Oncology · 2020 · 332 citations · Full text

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

Christopher D. Carey, Daniel Gusenleitner, Mikel Lipschitz et al. · Blood · 2017 · 325 citations · Full text

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

Anita K. Mehta, Emily Cheney, Christina Hartl et al. · Nature Cancer · 2020 · 239 citations · Full text

, , +8

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Xinqi Wu, Anita Giobbie‐Hurder, Xiaoyun Liao et al. · Cancer Immunology Research · 2016 · 161 citations · Full text

Rows per page

1–5 of 18